kr6.03
3.21%
Stockholm, Oct 03, 05:29 pm CET
ISIN
SE0002478776
Symbol
SEZI

Senzime Stock price

kr6.03
-0.36 5.63% 1M
+1.34 28.43% 6M
+0.53 9.64% YTD
-0.28 4.44% 1Y
-2.04 25.26% 3Y
-16.75 73.53% 5Y
+1.65 37.67% 10Y
-2.46 28.98% 20Y
Stockholm, Closing price Fri, Oct 03 2025
-0.20 3.21%
ISIN
SE0002478776
Symbol
SEZI

Key metrics

Basic
Market capitalization
kr979.5m
Enterprise Value
kr862.2m
Net debt
positive
Cash
kr132.2m
Shares outstanding
156.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.1 | 8.7
EV/Sales
10.7 | 7.6
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
81.1%
Return on Equity
-34.3%
ROCE
-28.7%
ROIC
-39.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr80.6m | kr113.2m
EBITDA
kr-89.1m | kr-85.7m
EBIT
kr-116.2m | kr-112.2m
Net Income
kr-126.4m | kr-127.7m
Free Cash Flow
kr-125.4m
Growth (TTM | estimate)
Revenue
71.4% | 93.6%
EBITDA
21.4% | 18.4%
EBIT
13.8% | 14.5%
Net Income
3.0% | -7.6%
Free Cash Flow
-0.5%
Margin (TTM | estimate)
Gross
40.8%
EBITDA
-110.5% | -75.7%
EBIT
-144.1%
Net
-156.8% | -112.8%
Free Cash Flow
-155.5%
More
EPS
kr-0.9
FCF per Share
kr-0.8
Short interest
-
Employees
54
Rev per Employee
kr1.1m
Show more

Is Senzime a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Financial data from Senzime

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
81 81
71% 71%
100%
- Direct Costs 48 48
45% 45%
59%
33 33
134% 134%
41%
- Selling and Administrative Expenses 132 132
6% 6%
164%
- Research and Development Expense 20 20
4% 4%
25%
-89 -89
21% 21%
-110%
- Depreciation and Amortization 27 27
26% 26%
34%
EBIT (Operating Income) EBIT -116 -116
14% 14%
-144%
Net Profit -126 -126
3% 3%
-157%

In millions SEK.

Don't miss a Thing! We will send you all news about Senzime directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. It manufactures products for automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patient's neuromuscular function perioperatively and in the intensive care medicine setting. The company also distributes bioreactor systems for the pharmaceutical industry. Senzime was founded by Thomas Ambjorn Carlsson in 1999 and is headquartered in Uppsala, Sweden.

Head office Sweden
CEO Mr. Siberg
Employees 54
Founded 1999
Website senzime.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today